Problems with malaria care quality among febrile under five children in 25 LMICs by treatment cascade
Country | Not blood tested* | Not treated with any drug† | Treated with only one malarial drug† | Receipt of treatment after 24 hours‡ | ||||
N | % | N | % | N | % | N | % | |
Tanzania (n=1413) | 1035 | 73% | 614 | 44% | 781 | 56% | 476 | 61% |
Nigeria (n=2213) | 1807 | 82% | 1465 | 69% | 623 | 29% | 425 | 63% |
Mozambique (n=1018) | 496 | 49% | 563 | 56% | 434 | 43% | 435 | 100% |
Mali (n=1655) | 1363 | 82% | 1193 | 75% | 366 | 23% | 283 | 71% |
Cambodia (n=1062) | 985 | 93% | 1060 | 100% | 1 | 0% | 1 | 100% |
Burkina Faso (n=2200) | 1367 | 62% | 1240 | 57% | 903 | 41% | 609 | 65% |
Madagascar (n=899) | 726 | 81% | 818 | 91% | 79 | 9% | 64 | 79% |
Togo (n=708) | 453 | 64% | 476 | 68% | 224 | 32% | 149 | 66% |
Zimbabwe (n=486) | 401 | 83% | 477 | 98% | 6 | 1% | 4 | 50% |
Angola (n=912) | 516 | 57% | 627 | 70% | 264 | 30% | 213 | 81% |
Namibia (n=433) | 332 | 77% | 417 | 96% | 13 | 3% | 13 | 81% |
Malawi (n=1082) | 554 | 51% | 754 | 71% | 310 | 29% | 174 | 56% |
Cameroon (n=1204) | 901 | 76% | 283 | 24% | 198 | 69% | ||
Ethiopia (n=624) | 532 | 86% | 83 | 13% | 85 | 100% | ||
Uganda (n=1329) | 822 | 62% | 1184 | 89% | 108 | 8% | 81 | 56% |
Rwanda (n=659) | 400 | 61% | 619 | 94% | 37 | 6% | 29 | 78% |
Gambia (n=371) | 221 | 60% | 354 | 96% | 14 | 4% | 8 | 57% |
Ghana (n=830) | 418 | 50% | 498 | 60% | 172 | 21% | 197 | 60% |
Kenya (n=1146) | 654 | 57% | 1114 | 97% | 25 | 2% | 18 | 58% |
Burundi (n=1068) | 514 | 48% | 930 | 87% | 127 | 12% | 69 | 50% |
Swaziland (n=586) | 582 | 99% | 4 | 1% | 4 | 100% | ||
Senegal (n=2926) | 2690 | 92% | 167 | 6% | 182 | 81% | ||
Zambia (n=2411) | 996 | 41% | 2299 | 95% | 107 | 4% | 87 | 78% |
Sierra Leone (n=1495) | 638 | 43% | 1405 | 94% | 68 | 5% | 54 | 64% |
Liberia (n=944) | 298 | 32% | 813 | 87% | 108 | 12% | 91 | 72% |
Total (n=29 674) | 14 996 | 23 625 | 5307 | 3949 | ||||
Mean | 62% | 82% | 17% | 72% |
There is no available information on blood testing in Cameroon, Ethiopia, Senegal and Swaziland. All data were analysed using survey weights.
*Among those with fever reported in the last 2 weeks.
†Among those with fever reported in the last 2 weeks and had a treatment encounter.
‡Among those with fever reported in the last 2 weeks and were treated with any malarial drug.
LMICs, low-income and middle-income countries.